The World Health Organization (WHO) has set an ambitious goal to eliminate viral hepatitis by 2030. But with over 250 million people living with Hepatitis B globally, why are we still falling short? In this episode, Dr. Robert Cykiert, founder, creator & host of #DoctorPodcasts, sits down with world-renowned viral hepatitis experts Dr. Tatyana Kushner, M.D. @TatyanaKushner (Weill Cornell Medicine) and Dr. Anu Osinusi, M.D., VP of Virology @GileadSciences, to break down the current state of liver disease, diagnosis, and treatment innovation. We dive deep into the silent differences between Hepatitis A, B, C, D, and E—uncovering how these viruses transmit, who is most at risk, and why Hepatitis B is so difficult to clear because it hides directly inside human DNA. Plus, we explore how Gilead Sciences is leveraging artificial intelligence (AI) to disrupt traditional drug development and collapse 15-year timelines into just a few years to find a functional cure. Video Timeline 0:00 – Introduction: The Global Burden of Viral Hepatitis 2:30 – What is Viral Hepatitis & How It Damages the Liver 4:04 – Shocking Global Statistics: Millions Affected Worldwide 4:54 – Gilead Sciences' Evolving Role in Fighting Liver Diseas 6:58 – Hepatitis A vs. B, C, D, & E: Key Differences Explained 7:14 – Modes of Transmission: Bloodborne vs. Fecal-Oral Routes 11:33 – Debunking Misconceptions: Can Saliva Transmit Hepatitis? 12:26 – Gilead's Current Research Priorities (HBV, HCV, HDV) 15:56 – The WHO 2030 Elimination Goal: Where Do We Stand? 17:27 – Screening Recommendations & Universal Pregnancy Testing20:12 – Addressing Hepatitis Delta: "The Forgotten Virus" 24:54 – Why Newborns & Immunosuppressed Patients Face Severe Risks 27:19 – Vaccine Guide: Who Needs the Hepatitis A & B Vaccines? 30:34 – Why Is Hepatitis B So Difficult to Eradicate? (DNA Integration) 33:10 – The Decline of Liver Transplants Due to Hepatitis C Cures 34:24 – The Next Frontier: Functional Cures for Hepatitis B37:41 – How Artificial Intelligence (AI) is Revolutionizing Drug Discovery40:46 – Trusted Online Resources for Patients & Families #HepatitisBCure #LiverHealth #MedicalAI #GileadSciences #PublicHealth #HepatitisAwareness

Is a new Ebola outbreak about to outpace the world? In this #DoctorPodcasts episode 151, two of the world's top epidemic responders break down the current crisis in the war-torn Democratic Republic of the Congo (DRC) and Uganda in Africa.Host Dr. Robert Cykiert, M.D. sits down with "Ebola Czar" Dr. Tolbert Nyenswah (Director of Public Health Emergency Management at Africa CDC) and frontline expert Dr. Daniel Bausch to discuss the Bundibugyo Ebola virus species. Discover why this rare strain currently lacks an effective vaccine, how active armed conflict is stalling contact tracing, and what the global community must do to stop a regional crisis from turning into a global threat. If you want to stay informed on global health security, please LIKE this video, SUBSCRIBE to the channel, and hit the NOTIFICATION BELL! Thanks.(Timestamps)0:00 - Introduction & US CDC Collaboration (p. 1)0:52 - Meet the Top Ebola Experts: Dr. Nyenswah & Dr. Bausch (pp. 1, 3)4:10 - Dr. Nyenswah’s Journey to Becoming the "Ebola Czar" (pp. 2-3)5:36 - Managing the Devastating 2014 West Africa Epidemic (pp. 2, 4)6:38 - How the Current DRC Outbreak Compares to 2014 (p. 5)8:45 - Frontline Realities: 50 Patients, 2 Doctors, No Vaccines (pp. 5-6, 8)12:07 - Busting Myths: How Ebola Actually Transmits (pp. 8-9)14:09 - Where the Current Epidemic Started & Major Cost Drivers (pp. 9-10)16:04 - The Critical Role (and Failure) of Contact Tracing (pp. 10-11)18:07 - Death Tolls: 2014 vs. Present Trajectory (p. 12)20:48 - The Bundibugyo Strain: Why There is No Vaccine (pp. 13-14)24:02 - Clinical Symptoms & The Power of Supportive Care (pp. 15-16)27:16 - Culture vs. Virus: Safe and Dignified Burial Practices (pp. 17, 20)33:54 - Africa CDC & WHO: A Unified Continental Plan (pp. 21-22)36:23 - Playing Catch-Up: Is the Outbreak Outpacing Us? (p. 23)40:08 - The Kenya Quarantine Center Controversy (pp. 25-26)46:10 - Civil Unrest & Broken Public Health Systems (pp. 29-30)49:43 - Can We Control It? A Call for Boots on the Ground (pp. 31-32) #EbolaOutbreak #GlobalHealth #MedicalPodcast #robertcykiertmd

In this #DoctorPodcasts Episode 149, we sit down with physician, Professor Carel le Roux, a global authority in metabolic medicine, #obesity and #diabetes to discuss the revolutionary shift in anti-obesity medications. We break down the differences between current leading GLP-1 drugs like #Ozempic (semaglutide) and #Mounjaro (tirzepatide), and look ahead to next-generation treatments. Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. We also explore Eli Lilly’s upcoming triple agonist, Retatrutide. If you want to understand the future of weight loss, #MetabolicHealth, and how these drugs target the brain-gut axis, this deep dive is for you.0:00 - Introduction & Guest Overview0:34 - Episode Welcome: Dr. Robert Cykiert0:48 - Entering Dublin: The GLP-1 Breakthrough2:27 - Long-Term Health Hazards of Obesity & Diabetes3:24 - Why Obesity is a Disease of the Brain, Not Willpower4:57 - Ozempic (Semaglutide) vs. Mounjaro (Tirzepatide)6:16 - The Fatty Liver Disease (MASLD/MASH) Epidemic7:50 - The Truth About Visceral vs. Ectopic Fat10:04 - Survodutide Explained: The New Dual Agonist12:45 - Managing Side Effects & Titration Schedules15:37 - Boehringer Ingelheim & the Future of Obesity Medicine16:48 - Retatrutide: Eli Lilly’s New Triple Agonist18:26 - A 30-Second Guide for Doctors & Patients20:11 - Closing Thoughts & Patient Transformations